Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Iti-007
2. Iti-722
3. Lumateperone
1. 1187020-80-9
2. Lumateperone (tosylate)
3. Iti-007 Tosylate
4. Iti 007
5. Lumateperone Tosylate [usan]
6. Jie88n006o
7. 1-(4-fluorophenyl)-4-[(10r,15s)-4-methyl-1,4,12-triazatetracyclo[7.6.1.05,16.010,15]hexadeca-5,7,9(16)-trien-12-yl]butan-1-one;4-methylbenzenesulfonic Acid
8. Lumateperone Tosylate (usan)
9. Lumateperone(iti-007)
10. Caplyta
11. Chembl3233142
12. Unii-jie88n006o
13. Caplyta (tn)
14. Schembl1769664
15. Iti-007iti-007
16. Dtxsid701026210
17. Lumateperone Tosylate [who-dd]
18. Cs-5540
19. Ac-36919
20. Bl167386
21. Hy-19733
22. Lumateperone Tosylate [orange Book]
23. D11170
24. A858354
25. Q27281520
26. 1-(4-fluoro-phenyl)-4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h,7h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one Tosylate Salt
27. 1-(4-fluorophenyl)-4-((6br,10as)-3-methyl-2,3,6b,7,10,10a-hexahydro-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9h)-yl)butan-1-one 4-methylbenzenesulfonate
28. 1-(4-fluorophenyl)-4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalin-8(7h)-yl)butan-1-one 4-methylbenzenesulfonate (1:1)
29. 1-(4-fluorophenyl)-4-[(6br,10as)-2,3,6b,9,10,10a-hexahydro-3-methyl-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl]-1-butanone 4-methylbenzenesulfonate
30. 1-butanone, 1-(4-fluorophenyl)-4-((6br,10as)-2,3,6b,9,10,10a-hexahydro-3-methyl-1h-pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalin-8(7h)-yl)-, 4-methylbenzenesulfonate (1:1)
1. Iti-722
2. 313368-91-1
3. Lumateperone
4. 70bsq12069
Molecular Weight | 565.7 g/mol |
---|---|
Molecular Formula | C31H36FN3O4S |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 565.24105597 g/mol |
Monoisotopic Mass | 565.24105597 g/mol |
Topological Polar Surface Area | 89.5 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 799 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-21
Pay. Date : 2023-08-17
DMF Number : 38206
Submission : 2023-03-31
Status : Active
Type : II
NDC Package Code : 71796-058
Start Marketing Date : 2023-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-05
Pay. Date : 2023-05-17
DMF Number : 38407
Submission : 2023-07-22
Status : Active
Type : II
NDC Package Code : 70966-0039
Start Marketing Date : 2019-12-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-18
Pay. Date : 2023-09-21
DMF Number : 38778
Submission : 2023-09-21
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-10-26
Pay. Date : 2023-09-22
DMF Number : 38730
Submission : 2023-09-20
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for relapse in adult patients with schizophrenia.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Intra-Cellular Reports Positive CAPLYTA Results for Schizophrenia Relapse Prevention
Details : Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for relapse in adult patients with schizophrenia.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 05, 2024
Details:
Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for the treatment of major depressive disorder.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Intra-Cellular Therapies Reports Positive Phase 3 Results for Lumateperone in Depression
Details : Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for the treatment of major depressive disorder.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 18, 2024
Details:
The intend to use the net proceeds from this offering to fund commercialization activities of Caplyta (lumateperone), which is indicated for the treatment of schizophrenia.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $575.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 24, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $575.0 million
Deal Type : Public Offering
Intra-Cellular Closes $575 Million Public Offering Including Underwriters' Option
Details : The intend to use the net proceeds from this offering to fund commercialization activities of Caplyta (lumateperone), which is indicated for the treatment of schizophrenia.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 24, 2024
Details:
Caplyta (lumateperone) proceeds will support continued commercialization in treating schizophrenia and bipolar depression.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 17, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Intra-Cellular Therapies Prices Public Offering of Common Stock
Details : Caplyta (lumateperone) proceeds will support continued commercialization in treating schizophrenia and bipolar depression.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 17, 2024
Details:
Caplyta (lumateperone) proceeds will support commercialization activities for its use in schizophrenia and bipolar depression treatment.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: J.P. Morgan
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 16, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $500.0 million
Deal Type : Public Offering
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Details : Caplyta (lumateperone) proceeds will support commercialization activities for its use in schizophrenia and bipolar depression treatment.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 16, 2024
Details:
Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for the treatment of major depressive disorder.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Intra-Cellular Announces Positive Phase 3 Results for Lumateperone in Depression
Details : Caplyta (lumateperone) is an oral, once daily atypical antipsychotic that acts as a 5-HT2A & D2 receptor antagonist. It is being evaluated for the treatment of major depressive disorder.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2024
Details:
Lumateperone tosylate capsule has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is used for the treatment of Schizophrenia.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta-Generic
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sun Pharma Gets CDSCO Panel Nod to Study Lumateperone Capsules
Details : Lumateperone tosylate capsule has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is used for the treatment of Schizophrenia.
Brand Name : Caplyta-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2023
Details:
Caplyta® (lumateperone) has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is investigated for the treatment of bipolar I or bipolar II disorder.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Caplyta® (lumateperone) has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is investigated for the treatment of bipolar I or bipolar II disor...
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2023
Details:
Caplyta® (lumateperone) has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is used for the treatment of major depressive disorers.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Caplyta® (lumateperone) has a combination mechanism of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. It is used for the treatment of major depressive disorers.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2023
Details:
The results confirm the favorable effects of Caplyta (lumateperone) 42mg on body weight and morphology as demonstrated by minimal and similar to placebo mean changes from baseline in weight, BMI (kg/m2) and waist circumference in short-term studies.
Lead Product(s): Lumateperone Tosylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Caplyta
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Lead Product(s) : Lumateperone Tosylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results confirm the favorable effects of Caplyta (lumateperone) 42mg on body weight and morphology as demonstrated by minimal and similar to placebo mean changes from baseline in weight, BMI (kg/m2) and waist circumference in short-term studies.
Brand Name : Caplyta
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
CAS Number : 96-30-0
End Use API : Lumateperone Tosylate
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...
4-Chloro-4'-fluorobutyrophenone
CAS Number : CAS-3874-54-2
End Use API : Lumateperone Tosylate
About The Company : Hebi Xinhe Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Zhennuo Pharmaceutical Group Co., Ltd., with a registered capital of CNY 100 million. Located in ...
Global Sales Information
Market Place
Reply
06 Aug 2024
Reply
14 Jul 2022
Reply
29 Jun 2022
Reply
21 Sep 2021
Reply
24 Jul 2020
Patents & EXCLUSIVITIES
Patent Expiration Date : 2028-03-12
US Patent Number : 10464938
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209500
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-03-12
Patent Expiration Date : 2039-08-30
US Patent Number : 11052084
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209500
Patent Use Code : U-3363
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-08-30
Patent Expiration Date : 2040-12-10
US Patent Number : 12122792
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209500
Patent Use Code : U-4019
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-12-10
Patent Expiration Date : 2040-12-10
US Patent Number : 11753419
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209500
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-12-10
Patent Expiration Date : 2029-02-12
US Patent Number : RE48825
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 209500
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-12
Patent Expiration Date : 2034-12-03
US Patent Number : 10960009
Drug Substance Claim :
Drug Product Claim :
Application Number : 209500
Patent Use Code : U-814
Delist Requested :
Patent Use Description : TREATMENT OF SCHIZOPHR...
Patent Expiration Date : 2034-12-03
Patent Expiration Date : 2033-08-19
US Patent Number : RE48839
Drug Substance Claim :
Drug Product Claim :
Application Number : 209500
Patent Use Code : U-814
Delist Requested :
Patent Use Description : TREATMENT OF SCHIZOPHR...
Patent Expiration Date : 2033-08-19
Patent Expiration Date : 2034-12-03
US Patent Number : 9956227
Drug Substance Claim :
Drug Product Claim :
Application Number : 209500
Patent Use Code : U-2714
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2034-12-03
Patent Expiration Date : 2029-03-12
US Patent Number : 9199995
Drug Substance Claim :
Drug Product Claim :
Application Number : 209500
Patent Use Code : U-2713
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-03-12
Patent Expiration Date : 2039-08-30
US Patent Number : 11806348
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209500
Patent Use Code : U-3363
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-08-30
ABOUT THIS PAGE
A Lumateperone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lumateperone, including repackagers and relabelers. The FDA regulates Lumateperone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lumateperone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lumateperone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lumateperone supplier is an individual or a company that provides Lumateperone active pharmaceutical ingredient (API) or Lumateperone finished formulations upon request. The Lumateperone suppliers may include Lumateperone API manufacturers, exporters, distributors and traders.
click here to find a list of Lumateperone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lumateperone DMF (Drug Master File) is a document detailing the whole manufacturing process of Lumateperone active pharmaceutical ingredient (API) in detail. Different forms of Lumateperone DMFs exist exist since differing nations have different regulations, such as Lumateperone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lumateperone DMF submitted to regulatory agencies in the US is known as a USDMF. Lumateperone USDMF includes data on Lumateperone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lumateperone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lumateperone suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lumateperone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lumateperone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lumateperone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lumateperone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lumateperone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lumateperone suppliers with NDC on PharmaCompass.
Lumateperone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lumateperone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lumateperone GMP manufacturer or Lumateperone GMP API supplier for your needs.
A Lumateperone CoA (Certificate of Analysis) is a formal document that attests to Lumateperone's compliance with Lumateperone specifications and serves as a tool for batch-level quality control.
Lumateperone CoA mostly includes findings from lab analyses of a specific batch. For each Lumateperone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lumateperone may be tested according to a variety of international standards, such as European Pharmacopoeia (Lumateperone EP), Lumateperone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lumateperone USP).
LOOKING FOR A SUPPLIER?